Frankfurt - Delayed Quote EUR

NurExone Biologic Inc. (J90.F)

Compare
0.4240
+0.0040
+(0.95%)
As of 8:04:58 AM GMT+1. Market Open.
Loading Chart for J90.F
DELL
  • Previous Close 0.4200
  • Open 0.4380
  • Bid 0.4220 x --
  • Ask 0.4440 x --
  • Day's Range 0.4240 - 0.4380
  • 52 Week Range 0.1670 - 0.9200
  • Volume 5,000
  • Avg. Volume 10,586
  • Market Cap (intraday) 30.059M
  • Beta (5Y Monthly) -0.09
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.

nurexone.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: J90.F

View More

Performance Overview: J90.F

Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

J90.F
0.47%
S&P/TSX Composite index
1.84%

1-Year Return

J90.F
146.51%
S&P/TSX Composite index
19.75%

3-Year Return

J90.F
35.03%
S&P/TSX Composite index
19.17%

5-Year Return

J90.F
35.03%
S&P/TSX Composite index
46.92%

Compare To: J90.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: J90.F

View More

Valuation Measures

As of 1/3/2025
  • Market Cap

    30.20M

  • Enterprise Value

    27.77M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    10.44

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -114.31%

  • Return on Equity (ttm)

    -253.66%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -4.14M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.38M

  • Total Debt/Equity (mrq)

    0.97%

  • Levered Free Cash Flow (ttm)

    -2.4M

Research Analysis: J90.F

View More

People Also Watch